Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health Care Use and Outcomes in Heart Failure: Are There Lingering Impacts From the COVID-19 Pandemic?

JACC. Advances·2026
Same author

Patient-physician familiarity is just as important for virtual outpatient encounters as for in-person encounters: a retrospective cohort study.

Scientific reports·2026
Same author

New and persistent psychoactive medication use in intensive care unit survivors with COVID-19: a multicentre population-based cohort study.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2026
Same author

Changes in Hypertension Prevalence and Control in Canada After the COVID-19 Pandemic: Insights From the Canadian Health Measures Survey Cycle 7.

The Canadian journal of cardiology·2026
Same author

Machine learning model for predicting improvement in left ventricular systolic function in patients with heart failure and reduced ejection fraction.

International journal of cardiology. Heart & vasculature·2026
Same author

Outcomes and Patterns Related to Magnesium in Acute Heart Failure: A Population-Based Study.

The Canadian journal of cardiology·2026

Related Experiment Video

Updated: May 23, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Testosterone supplementation in heart failure: a meta-analysis.

Mustafa Toma1, Finlay A McAlister, Erin E Coglianese

  • 1St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

Circulation. Heart Failure
|April 19, 2012
PubMed
Summary

Testosterone therapy significantly improved exercise capacity in men with heart failure (HF). This finding suggests a promising treatment option for enhancing functional ability in this patient group, with no observed adverse cardiovascular events.

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Related Experiment Videos

Last Updated: May 23, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Area of Science:

  • Cardiology
  • Endocrinology
  • Exercise Physiology

Background:

  • Low testosterone is linked to reduced exercise capacity and poor outcomes in heart failure (HF) patients.
  • Stable chronic heart failure patients often experience diminished functional capacity.

Purpose of the Study:

  • To evaluate if testosterone therapy enhances exercise capacity in stable chronic heart failure patients.
  • To determine the efficacy of testosterone supplementation in improving physical function for heart failure individuals.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) published between 1980-2010.
  • Included four RCTs with 198 male participants (mean age 67 years).
  • Assessed exercise capacity using the 6-minute walk test, incremental shuttle walk test, and peak oxygen consumption.

Main Results:

  • Testosterone therapy demonstrated a significant improvement in exercise capacity compared to placebo.
  • Mean improvements observed: 54.0m in 6-minute walk test, 46.7m in incremental shuttle walk test, and 2.70 mL/kg/min in peak oxygen consumption.
  • No significant adverse cardiovascular events were reported during the treatment period.

Conclusions:

  • Testosterone therapy shows promise for improving functional capacity in heart failure patients.
  • Further large-scale RCTs are needed to confirm benefits for quality of life, clinical events, and safety in this high-risk population.